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patients are faced with a choice of treatment options: radical
prostatectomy or radio therapy. Although this different treat-
ments may have no differences in terms of survival, they may
have very different consequences on the subsequent quality of
life (QoL). Prerequisite to answer these questions is a reliable and
valid instrument to assess these differences. Since in Europe the
EORTC QLQ-C30 became the standard instrument to evaluate
QoL in cancer patients, the task was to develop a disease spe-
ciﬁc module in addition to the core questionnaire to assess not
just general QoL but as well prostate speciﬁc symptoms.
METHODS: Between 1996 and 2000 different groups con-
ducted historical cohort studies using the EORTC QLQ-C30 and
a prostate speciﬁc module developed by Kuechler et al. The Ref-
erence Center Quality of Life in Germany put together these
studies for an empirical meta-analysis. The main objective was
to analyze the module’s psychometric properties. The total
sample consisted of 1185 patients, of which 950 completed the
QoL questionnaires. These 950 questionnaires were included in
a detailed psychometric analysis. RESULTS: First step of this
psychometric analysis was a principal component analysis,
which revealed the scales: urinary problems, incontinence, erec-
tile dysfunction, sexual problems, problems with partner, pain,
heat, nutrition, and psychic strain. Their reliabilities indicated
good to sufﬁcient internal consistency with a Cronbach’s alpha
(0.70 to 0.89 except to two scales). The module showed good
concurrent validity (correlations with “Global Health” from the
EORTC QLQ-C30) and very good construct validity, since the
module is able to discriminate between different treatment
regimes, tumour stages and age. CONCLUSIONS: The prostate
speciﬁc module is a reliable, valid and applicable measure for
quality of life in patients with prostate cancer.
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OBJECTIVES: Condition-speciﬁc preference indices (COPI’s)
may provide a sensitive measure of treatment effect and eco-
nomic impact in certain disorders. Our goal was to adapt the
Barthel Index, a validated 10-item measure of physical disabil-
ity, as a COPI for stroke clinical trials and practice settings. The
resulting instrument is known as the Barthel Preference Index
(BPI). METHODS: Preferences were elicited from 152 commu-
nity members (≥45 years) using visual analog scaling (VAS) and
discrete choice experiment (DCE). Ordinary least squares and
probit regression models were developed from VAS and DCE
data, respectively, and indexed from zero to one. Data from
stroke inpatients were used to calculate preferences for com-
monly occurring stroke disability states. Tests of internal consis-
tency, and construct, convergent and discriminant validity were
performed. RESULTS: Thirty-one percent of the subjects were
male, mean age was 61 years, 88% were Caucasian, 60% had
more than a high school education, and 63% were married. VAS
preferences ranged from 0.09 to 0.40 for severe and very severe
stroke, 0.40 and 0.74 for moderate stroke, and 0.72 to 0.97 for
mild stroke. DCE preferences ranged from 0.04 to 0.17, 0.17 to
0.76, and 0.47 to 0.88, respectively. Multiple preferences were
observed within individual BI scores. Both models demonstrated
internal consistency, and construct and convergent validity.
Spearman correlations between VAS and DCE utilities, and BI
scores were 96% and 91%, respectively. The correlation between
VAS and DCE utilities was 94%. Overall, the VAS model was
stronger and demonstrated superior discriminant validity. CON-
CLUSIONS: The Barthel Preference Index, a COPI intended 
for stroke clinical trials and practice, was found to be valid and
reliable in this population. Multiple preferences within scores
suggest that the BPI may be more sensitive to treatment effect
than BI scores. Further validation and tests of responsiveness in
clinical trials are required.
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OBJECTIVES: To develop and validate a self-administered ques-
tionnaire assessing the “severity” and “bothersomeness” of the
most frequently reported symptoms and signs of uncomplicated
urinary tract infection (uUTI). METHODS: The UTI Symptoms
Assessment (USA) questionnaire—a 14-item instrument asking
about the severity and bothersomeness of seven key uUTI symp-
toms—was completed by 276 women with uUTI who had 
participated in a prospective, open-label, non-comparative mul-
ticentre clinical trial of CIPRO® XR (ciproﬂoxacin extended-
release tablets). Subjects completed the USA in electronic format
at baseline and at varying time intervals until the test of cure
(TOC) visit. Baseline scores on the King’s Health Questionnaire
(KHQ) were collected and Global Rating of Change (GRC) items
were completed with each USA administration. An investigator
performed a clinical evaluation of UTI symptoms at baseline and
TOC visit. RESULTS: On unforced principal components factor
analysis, the USA was found to comprise three four-item
domains named Urination Regularity, Problems with Urination,
and Pain Associated with UTI. Two questions asking about
haematuria loaded on a fourth factor. The three domains were
homogeneous and internally consistent, each having Cronbach’s
alpha scores of 0.80–0.90. Convergent validity of the USA was
shown by high correlations between similar USA and KHQ
domains (all rs > 0.40), and divergent validity by small correla-
tions between unlike domains (all rs < 0.15). The USA domains
demonstrated excellent discriminant validity (to clinical
symptom evaluations) and responsiveness to changes in clinical
evaluation and GRC items. Symptom improvement was highest
in the ﬁrst three hours, leading to greater responsiveness and
MID during this period. CONCLUSIONS: The three-domain
USA has excellent psychometric properties: each domain shows
high levels of internal reliability, convergent and divergent valid-
ity, discriminant validity and responsiveness. The USA is thus
likely to prove an excellent tool for assessing uUTI outcome from
a patient’s perspective, in both research and clinical settings.
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OBJECTIVES: In non-insulin-dependent diabetes mellitus
(NIDDM) where auto-treatment plays an important role in
disease management, patient satisfaction is particularly impor-
